SP-420

DRUG5 trials

Sponsors

Pharmacosmos A/S, Sideris Pharmaceuticals, Abfero Pharmaceuticals, Inc, The University of Texas Health Science Center at San Antonio

Conditions

Beta Thalassemia Major AnemiaBeta-ThalassemiaIron OverloadMyelodysplastic SyndromeTransfusion-dependent ß-thalassemia TDT

Phase 1

Safety and Pharmacokinetic Study of Escalating Doses of SP-420, an Iron Chelator, in Patients With β-Thalassemia

TerminatedNCT02274233

Sideris PharmaceuticalsBeta-Thalassemia, Iron Overload

Start: 2014-10-31End: 2015-09-30Updated: 2015-09-29

Safety of SP-420 in the Treatment of Transfusional Iron Overload

TerminatedNCT04741542

The University of Texas Health Science Center at San AntonioIron Overload

Start: 2021-03-09End: 2024-01-10Updated: 2024-12-27

Phase 2

SP-420 in Subjects With Transfusion-dependent Beta-Thalassemia or Other Rare Anemias

WithdrawnNCT03801889

Abfero Pharmaceuticals, IncBeta-Thalassemia, Iron Overload

Start: 2020-08-31End: 2023-01-31Updated: 2020-10-05

A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia or Low-risk Myelodysplastic Syndromes

RecruitingNCT05693909

Pharmacosmos A/SBeta Thalassemia Major Anemia, Myelodysplastic Syndrome

Start: 2023-09-04End: 2028-05-31Target: 90Updated: 2025-09-24

An open-label, dose-escalation, dose-finding, and proof-of-concept trial of SP-420 in subjects with transfusion-dependent ß-thalassemia

Active, not recruitingLBCTR2023045220

Pharmacosmos A/STransfusion-dependent ß-thalassemia TDT

Start: 2023-04-24Target: 90Updated: 2026-02-02